Philip James Wealth Mangement LLC Invests $15.39 Million in Organon & Co. (NYSE:OGN)

Philip James Wealth Mangement LLC bought a new position in Organon & Co. (NYSE:OGN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 804,262 shares of the company's stock, valued at approximately $15,386,000. Organon & Co. comprises approximately 1.9% of Philip James Wealth Mangement LLC's portfolio, making the stock its 8th largest position. Philip James Wealth Mangement LLC owned approximately 0.31% of Organon & Co. as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Mercer Global Advisors Inc. ADV lifted its position in Organon & Co. by 1.8% during the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company's stock valued at $674,000 after buying an additional 546 shares in the last quarter. Ballentine Partners LLC raised its stake in shares of Organon & Co. by 3.0% during the second quarter. Ballentine Partners LLC now owns 19,105 shares of the company's stock valued at $395,000 after purchasing an additional 552 shares during the period. Atomi Financial Group Inc. raised its stake in shares of Organon & Co. by 1.8% during the first quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company's stock valued at $618,000 after purchasing an additional 593 shares during the period. Bill Few Associates Inc. raised its stake in shares of Organon & Co. by 5.4% during the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company's stock valued at $253,000 after purchasing an additional 621 shares during the period. Finally, Sippican Capital Advisors raised its stake in shares of Organon & Co. by 4.3% during the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company's stock valued at $291,000 after purchasing an additional 627 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of Organon & Co. stock traded down $0.08 during trading on Friday, hitting $16.04. 2,570,011 shares of the stock were exchanged, compared to its average volume of 2,241,378. The stock's fifty day moving average is $18.89 and its 200 day moving average is $20.06. The stock has a market cap of $4.13 billion, a PE ratio of 3.20, a P/E/G ratio of 0.76 and a beta of 0.84. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.17 and a current ratio of 1.70. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm's revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 EPS. As a group, sell-side analysts anticipate that Organon & Co. will post 4.04 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be given a $0.28 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 6.98%. Organon & Co.'s dividend payout ratio is presently 22.22%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered shares of Organon & Co. from a "neutral" rating to an "underweight" rating and lifted their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI raised shares of Organon & Co. to a "strong-buy" rating in a report on Wednesday, September 18th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.